Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1994-02-28
1996-06-25
Cintins, Marianne M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514 29, A61K 3133, A61K 3170
Patent
active
055299946
ABSTRACT:
A method of reducing the severity of toxoplasmosis resulting from infection of a patient with Toxoplasma gondii by administering to a patient in need of such treatment, either after infection or before exposure to infection, a therapeutically effective amount of a compound that is a spiropiperidyl derivative of rifamycin S, wherein the derivative comprises an imidazole ring that includes carbons at positions 3 and 4 of the rifamycin ring, the carbon at position 2 of the imidazole ring also being a ring carbon at position 4 of a piperidine ring system, thereby forming a spiropiperidyl ring system, the spiropiperidyl ring system optionally comprising a lower hydrocarbon substituent on the nitrogen of the piperidine.
REFERENCES:
patent: 4086225 (1978-04-01), Marsili et al.
patent: 4219478 (1980-08-01), Marsili et al.
patent: 4327096 (1982-04-01), Marsili et al.
patent: 4738958 (1988-04-01), Franco et al.
patent: 4963531 (1990-10-01), Remington
Remington, J. S. and Desmonts, G. : In Infectious Diseases of the Fetus and Newborn Infant, 3rd Ed., J. S. Remington, J. O. Klein, eeds Philadelphia: WB Saunders Company (1990) pp. 89-195.
Remington, J. S. et al. "The effect of Rifampin Toxoplasma gondii" (1970) Proc. Soc. Ex. Biot. and Med: 135: 167-172.
Singleton, P. and Sainsbury, D. eds. (1987) Dictionary of Microbiology and Molecular Biology, 2nd Ed., John Wiley and Sons, Ltd. Bath (England) p. 769.
Physicians Desk Reference (1993) : pp. 1394-1397.
Woodley, C. L. and Kilburn, J. O. (1982) Am. Rev. Respir. Dis. 126:586-587.
Hoy, J. et al. (1990) J. Infect. Dis. 161: 801-805.
Araujo, F. G. et al. (1993) J. Infect. Dis. 167:494-7.
Ruskin, J. and Remington, J. S. (1976) Ann. Intern. Med. 84:193-199.
O'Brien, R. J. et al. (1987) Review of Infectious Diseases 9:519-529.
Araujo, F. G. (1992) Depletion of CD4+ T Cells but Not Inhibition of the Protective Activity of IFN-y J. Immunol. 149:3003-3007.
Araujo, F. G. et al. (1991) In Vivo Activity of the Macrolide Eur. J. Clin. Microbiol. Infect. Dis. 10:519-542.
Araujo, F. G. et al. (1992) In Vitro and In Vitro Activities of the Hydroxynaphthoquinone 566C80 Against the Cyst Form of Toxoplasma gondii. Antimocrob. Agents Chemother. 36:326-330.
Araujo, F. G. et al. (1991) Remarkable In Vitro and In Vitro Activities of the Hydroxynaphthoquinone 566C80 Against Tachyzoites and Cysts of Toxoplasma Gondii. Antimocrob. Agents and Chemother. 35:293-299.
Araujo, F. G. et al. (1992) Clarithromycin--minocycline Is Synergistic in a Murine Model of Toxoplasmosis. J. Infect. Dis. 165:788.
Chiodini, R. J. et al. (1993) Use of Rifabutin in Treatment of Systemic Mycobacterium Paratuberculosis Infection in Mice. Antimicrob. Agents Chemother. 37:1645-1648.
Dannemann, B. et al. (1992) Treatment of Toxoplasmic Encephalitis in Patients With Acquired Immunodeficiency Syndrome. Ann. Intern. Med. 116:33-43.
Dannemann, B. et al. (1988) Treatment of Toxoplasmic Encephalitis with Intravenous Clidamycin. Arch. Intern. Med. 148:2477-2482.
Ellner, J. J. et al. (1991) Mycobacterium Avium Infection in Aids. J. Infect. Dis. 163:1326-1335.
Heifets, L. B. et al. Bacteriostatic and Bactericidal Effects of Rifabutin (Ansamycin, LM 427) on Mycobacterium Avium Clinical Isolates, p. 180-183. In M. Casal (ed.) Mycobacteria of Clinical Interest-(1986) Amesterdam: Elsevier Science.
Horsoburgh, C. R. (1991). Myobacterium Avium Complex Infections in the Acquired Immunodeficiency Syndrome. N. Engl. J. Med. 324:1332-1338.
Hughes, W. T. et al. (1991) Safety and Pharmacokinetics of 566C80, a Hydroxynaphtoquinone with Anti-Pneumocystis Carinii Activity. J. Infect. Dis. 163:843-848.
Isrealski, D. M. et al. Toxoplasmosis in Patients with AIDS, p. 241-264 In M. A. Sande and P. A. Volberding (eds.) The Medical Management of AIDS--1990. Philadelphia: W. B. Sounders.
Isrealski, D. M. et al. (1989) Treatment with Anti-L3T4 (CD4) Monoclonal Antibody Reduces the Inflammatory Response in Toxoplasmic Encephalitis. J. Immunol. 142:954-958.
Narang, P. K. et al. (1992) Rifabutin Absorption in Humans; Relative Bioavailability and Food Effect. Clin. Parmac. Therap. 52:335-341.
McCabe, R. E. et al. Toxoplasma gondii, pp. 2090-2103. In Third ed. Principles and Practice of Infectious Diseases--1990. G. L. Mandell et al. (eds.) London: Churchhill Livingstone, Inc.
Hunter, C. A. et al. (1993) Cytokine mRNA in the Central Nervous System of SCID Mice Infected With Toxoplasma Gondii. Infect. Immun. 61:4038-4044.
Araujo Fausto G.
Remington Jack S.
Cintins Marianne M.
Palo Alto Medical Foundation
Weddington Kevin E.
LandOfFree
Treatment for toxoplasmosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment for toxoplasmosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment for toxoplasmosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2188941